Stock comparison
Apellis Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
APLS
Apellis Pharmaceuticals
Market cap
$5.25B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | APLS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 75B | IDXX |
| Benjamin Graham | 79D | 80A | IDXX |
| Philip Fisher | 71C | 75B | IDXX |
| Peter Lynch | 81C | 71B | APLS |
| Joel Greenblatt | 63C | 83C | IDXX |
| Charlie Munger | 67D | 87A | IDXX |
| Terry Smith | 65B | 84A | IDXX |
Side-by-side metrics
| Metric | APLS | IDXX |
|---|---|---|
| Market cap | $5.25B | $44.12B |
| P/E (TTM) | 38.8x | 39.0x |
| EV/EBIT | 96.0x | 31.6x |
| ROIC (TTM) | 18.11% | 40.66% |
| Gross margin | 90.12% | 62.05% |
| Net margin | 12.06% | 24.63% |
| Revenue CAGR 5y | 97.06% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 1.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs 7.56%+92%
- Gross margin90.12%vs 62.05%+31%
IDXX leads on
- Market cap$44.12Bvs $5.25B+88%
- EV/EBIT31.6xvs 96.0x+67%
- ROIC (TTM)40.66%vs 18.11%+55%
- Net margin24.63%vs 12.06%+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.